Artelo Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>AB</div>
ARTL -- USA Stock  

USD 1.95  0.24  10.96%

As many millenniums are trying to avoid healthcare space, it makes sense to summarize ARTELO BIOSCIENCES INC a little further and try to understand its current market patterns. We are going to address the reasons why we are still confident in anticipation of a recovery. ARTELO BIOSCIENCES INC barely shadows the market. The returns on investing in ARTELO BIOSCIENCES and the market returns of the last few months appear not related. Steady essential indicators of the company may denote signs of medium-term price drift for stakeholders. The stock continues to experience an active upward rally.
Published over a week ago
View all stories for Artelo Biosciences | View All Stories
Our new technical analysis of ARTELO BIOSCIENCES INC (NASDAQ:ARTL)
ARTELO BIOSCIENCES's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on ARTELO BIOSCIENCES market sentiment investors' perception of the future value of ARTELO. Let us look at a few aspects of ARTELO technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Artelo Biosciences. In general, we focus on analyzing Artelo Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Artelo Biosciences's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Artelo Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Artelo Biosciences, we also check how macroeconomic factors affect Artelo Biosciences price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Artelo Biosciences' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Artelo Biosciences in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Artelo Biosciences. Your research has to be compared to or analyzed against Artelo Biosciences' peers to derive any actionable benefits. When done correctly, Artelo Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Artelo Biosciences.

How does Artelo Stands against Peers?

Analyzing Artelo Biosciences competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Artelo Biosciences across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Artelo Biosciences Competition Details

How Artelo utilizes its cash?

To perform a cash flow analysis of Artelo Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Artelo Biosciences is receiving and how much cash it distributes out in a given period. The Artelo Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Artelo Biosciences Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (4.02 Million)

Closer look at ARTELO BIOSCIENCES Semi Variance

ARTELO BIOSCIENCES INC has current Semi Variance of 17.16. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.

Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Variance 
 = 
SUM(RET DEV)2 
N(ZERO) 
 = 
17.16
SUM = Summation notation
RET DEV = Actual return deviation over selected period
N(ZERO) = Number of points with returns less than zero
Let's now compare ARTELO BIOSCIENCES Semi Variance to its closest peers:
ARTL
EQ
NK
DMAC
DNLI
ARTL17.16175350493596
EQ27.71
NK20.31
DMAC13.47
DNLI20.88

A growth case for ARTELO BIOSCIENCES

New downside variance is at 23.89. ARTELO BIOSCIENCES INC is displaying above-average volatility over the selected time horizon. Investors should scrutinize ARTELO BIOSCIENCES INC independently to ensure intended market timing strategies are aligned with expectations about ARTELO BIOSCIENCES volatility.

Our Bottom Line On ARTELO BIOSCIENCES INC

While many of the other players in the biotechnology industry are either recovering or due for a correction, ARTELO may not be as strong as the others in terms of longer-term growth potentials. All things considered, as of the 13th of February 2021, we believe that at this point, ARTELO BIOSCIENCES is overvalued with below average chance of financial distress within the next 2 years. Our final recommendation on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Artelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com